跳至主要内容
临床试验/NCT00005861
NCT00005861已完成2 期

Evaluation of Doxil as First-Line Therapy of Advanced or Recurrent Endometrial Carcinoma

Gynecologic Oncology Group20 个研究点 分布在 1 个国家开始时间: 2000年5月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
试验地点
20

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating women who have recurrent, stage III, or stage IV endometrial cancer.

详细描述

OBJECTIVES:

  • Determine the antitumor activity and safety of doxorubicin HCl liposome in patients with advanced or recurrent endometrial cancer.
  • Determine the response rate, response duration, and overall survival of these patients treated with this regimen.

OUTLINE: Patients receive doxorubicin HCl liposome IV over 1 hour. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Network

研究点 (20)

Loading locations...

相似试验